|
業務類別
|
Software - Infrastructure |
|
業務概覽
|
TAO Synergies Inc is mainly focused on developing a product platform based on its drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease. The company is also evaluating Bryostatin-1 for other neurodegenerative and cognitiveconditions, including Fragile X syndrome and Multiple Sclerosis, which have progressed through pre-clinical testing. |
| 公司地址
| -- |
| 電話號碼
| -- |
| 傳真號碼
| -- |
| 公司網頁
| https://www.taosynergies.com |
| 員工數量
| -- |
| Mr. Robert Weinstein |
Chief Financial Officer, Secretary, Treasurer, Principal Accounting Officer and Executive Vice President |
美元 348.41K |
31/03/2026 |
|
|
| Mr. Robert Ephron |
Director |
31/03/2026 |
| Mr. Bruce T. Bernstein |
Vice Chairman of the Board |
31/03/2026 |
| Mr. Joshua Nathaniel Silverman |
Executive Chairman of the Board |
31/03/2026 |
| Mr. William S. Singer |
Independent Director |
31/03/2026 |
|
|
|
|
